AMX0035
Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo
Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation
Actionable Insights Powered by AI
Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation